---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-303234"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:31:51.196089+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Frequency Therapeutics expects FX-322-208 trial results in H2 Q1 2023

## Summary
- Posted updated corporate slide presentation on Dec 13, 2022.
- FX-322-208 Phase 2 trial results expected second half of Q1 2023.
- FX-322 is an investigational regenerative therapy for sensorineural hearing loss.

## SEC filing metadata
- accession: 0001193125-22-303234
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312522303234/0001193125-22-303234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312522303234/d425973d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-303234
- JSON: https://secwatch.observer/filing/0001193125-22-303234.json
- Plain text: https://secwatch.observer/filing/0001193125-22-303234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.